findmyKOL

Ivan Borrello, MD

Enriched profile

Medical Director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies Program, TGH Cancer Institute · Tampa General Hospital Cancer Institute

ORCIDNPI
Region🇺🇸 Tampa, FL · Southeast · United StatesSpecialtyMedical OncologyFocusMultiple Myeloma Research and Treatments+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH fundingNone on fileWhy? →

Ivan Borrello is Medical Director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies Program, TGH Cancer Institute at Tampa General Hospital Cancer Institute. OpenAlex indexes 282 publications with 21,949 citations (h-index 60); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Ivan Borrello, MD, is Medical Director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies Program, TGH Cancer Institute at Tampa General Hospital Cancer Institute. The public record shows 282 publications with 21,949 citations (h-index 60), centered on Multiple Myeloma Research and Treatments, Immunotherapy and Immune Responses, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 33 companies.

  • Most recent indexed publication: 2025 · Journal for immunotherapy of cancer
  • Top research focus: Multiple Myeloma Research and Treatments
  • 7 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 33 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Myeloma7 trials

Research focus

OpenAlex concept fingerprint
Multiple Myeloma Research and TreatmentsImmunotherapy and Immune ResponsesHematopoietic Stem Cell TransplantationCAR-T cell therapy researchImmune Cell Function and Interaction

Drugs & molecules

across trials, industry payments and publications
Revlimidgeneric · LenalidomideClinical trialsIndustry payments1Publications1Sarclisageneric · IsatuximabClinical trialsIndustry payments49PublicationsLyfgeniageneric · Lovotibeglogene autotemcelClinical trialsIndustry payments13Publications

Works with

trial sponsors and companies reporting payments
Genzyme CorporationClinical trialsIndustry payments49McKesson Sourcing Services, Inc.Clinical trialsIndustry payments30Regeneron Healthcare Solutions, Inc.Clinical trialsIndustry payments12

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
282publications

Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.

21,949citations

Total citations across indexed works.

60h-index

Hirsch index (OpenAlex). i10-index 120.

Clinical & industry

trials, payments and federal funding
7clinical trials

Investigator role on registered studies.

View trials
33companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    36.7%
    Thalidomide Analog26.2%
    Lenalidomide63%Revlimid37%
    Part D<11 patients
    BCL-2 Inhibitor5.9%
    Venclexta100%
    Part D<11 patients
  • Dermatology

    21.5%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor21.5%
    Acyclovir100%
    Part D11 patients
  • Anti-infectives

    12.2%
    Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor7.6%
    Entecavir100%
    Part D<11 patients
    Short-acting sulfonamides4.6%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
3 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

32 congress contributions (2004–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Carol Ann Huff91Kimberly Noonan81Richard J. Jones56

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/ivan-borrello-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • LinkedIn

    linkedin.com/in/ivan-borrello-912bab7

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/profile/Ivan-Borrello-3

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net

Mentions by others

where others cite or feature them
  • Apple Podcasts

    podcasts.apple.com/us/podcast/myeloma-crowd-radio-ivan-borrello-md-johns-hopkins/id683926347

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com
  • Other

    crunchbase.com/person/ivan-borrello

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →crunchbase.com
  • YouTube

    youtube.com/watch

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    Medical College of Virginia (Virginia Commonwealth University School of Medicine), Richmond

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.tgh.org
  • Internal Medicine residency

    University of Chicago

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.tgh.org
  • Medical Oncology fellowship

    Johns Hopkins Oncology Center, Johns Hopkins University

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →getcare.tgh.org

Editorial & leadership roles

journal and society appointments
  • Member

    Hematologic Malignancies and Bone Marrow Translational Program / Cancer Immunology Working Group, American Association for Cancer Research (AACR)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.